ARTICLE | Distillery Therapeutics
Autoimmune disease
January 8, 2019 10:18 PM UTC
In vitro and mouse studies identified an NR1D1 agonist that could help treat MS. Optimization and in vitro binding assays of analogs of a previously reported benzohydrazide-based NR1D1 agonist yielded...
BCIQ Company Profiles
BCIQ Target Profiles
Nuclear receptor subfamily 1 group D member 1 (NR1D1) (Rev-ErbAalpha)